Advertisement


Curtis Lachowiez, MD, on AML: Venetoclax Combined With FLAG-IDA

SOHO 2021

Advertisement

Curtis Lachowiez, MD, of The University of Texas MD Anderson Cancer Center, discusses data that show combining venetoclax with FLAG-IDA chemotherapy to treat patients with newly diagnosed acute myeloid leukemia led to minimal residual disease negativity in more than 90% of those achieving a composite complete response (Abstract AML-024).



Related Videos

Advertisement

Advertisement



Advertisement